Added by | tchardes |
---|---|
Group name | EquipeELC |
Item Type | Journal Article |
Title | Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers |
Creator | Jacot et al. |
Author | William Jacot |
Author | Aurélie Maran-Gonzalez |
Author | Océane Massol |
Author | Charlotte Sorbs |
Author | Caroline Mollevi |
Author | Séverine Guiu |
Author | Florence Boissière-Michot |
Author | Jeanne Ramos |
Abstract | HER2-low breast cancer (i.e., HER 1+ or 2+, without gene amplification) is an emerging subtype for which very few data are available, especially within the triple-negative breast cancer (TNBC) group. Our aim was to evaluate HER2 expression and its prognostic value in a large retrospective series of patients with non-metastatic TNBC (median age: 57.7 years; range: 28.5-98.6). Among the 296 TNBC samples, 83.8% were HER2 0, 13.5% were HER2 1+, and 2.7% were HER2 2+ (HercepTestTM and 2018 ASCO/CAP guidelines for HER2 scoring). CK5/6 and/or EGFR-expressing androgen receptors and FOXA1-expressing tumors were classified as basal-like (63.8%) and molecular apocrine-like (MA, 40.2%), respectively. Compared with HER2 0 tumors, HER2 1+/2+ tumors exhibited a lower histological grade (1/2) (35.4% vs. 18.2%, p = 0.007) and MA profile (57.5% vs. 36.7%, p = 0.008). Moreover, patients with HER2 1+/2+ tumors were older (p = 0.047). After a median follow-up of 9.7 years, HER2 2+ tumors (compared with HER2 0/1+ tumors) were associated with worse relapse-free survival (RFS) (HR = 3.16, 95% CI [1.27; 7.85], p = 0.034) in a univariate analysis. Overall survival (OS) and RFS were not different in the HER2 0 and 1+/2+ groups. HER2 levels were not significantly associated with OS or RFS in a multivariate analysis. |
Publication | Cancers |
Volume | 13 |
Issue | 23 |
Pages | 6059 |
Date | 2021-12-01 |
Journal Abbr | Cancers (Basel) |
Language | eng |
DOI | 10.3390/cancers13236059 |
ISSN | 2072-6694 |
Library Catalog | PubMed |
Extra | PMID: 34885167 PMCID: PMC8656488 |
Tags | clinic, expression, HER2-low, molecular apocrine |
Date Added | 2022/01/14 - 09:42:52 |
Date Modified | 2022/02/08 - 09:23:12 |
Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |